Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VRDN-001
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Fairmount Funds Management LLC
Deal Size : $91.0 million
Deal Type : Financing
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.
Details : Company plans to use private placement financing proceeds of $91 million to advance multiple compounds through phase 2 proof of concept studies in TED and to expand its orphan disease pipeline.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
October 28, 2020
Lead Product(s) : VRDN-001
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Fairmount Funds Management LLC
Deal Size : $91.0 million
Deal Type : Financing
Lead Product(s) : VRDN-001
Therapeutic Area : Immunology
Study Phase : IND Enabling
Recipient : Viridian Sciences
Deal Size : Undisclosed
Deal Type : Acquisition
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc
Details : miRagen gains Viridian's clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, a clinical-stage insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) to treat thyroid eye disease.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
October 28, 2020
Lead Product(s) : VRDN-001
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Recipient : Viridian Sciences
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : MRG-110
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data demonstrate that a single systemic dose of MRG-110 reduced detectable miR-92a levels in the peripheral blood of humans and led to the regulation of several well established miR-92a target genes.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 28, 2020
Lead Product(s) : MRG-110
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cobomarsen
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma
Details : Cobomarsen is an inhibitor of miR-155 currently being developed by miRagen in two clinical programs to address different types of T-cell lymphoma, including a Phase 2 trial for cutaneous T-cell lymphoma (CTCL) and a Phase 1 trial for adult T-cell leukemi...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 23, 2020
Lead Product(s) : Cobomarsen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MRG-229
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MRG-229 has demonstrated mechanistic biomarker regulation and antifibrotic activity in vitro using human model systems.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 22, 2020
Lead Product(s) : MRG-229
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cobomarsen
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cobomarsen lacks a compelling result for the study's primary endpoint, objective skin response of at least four months duration (ORR4) relative to the vorinostat control arm.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 10, 2020
Lead Product(s) : Cobomarsen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cobomarsen
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : miRagen Therapeutics is conducting a Phase 1 trial of cobomarsen in adult T-cell leukemia/lymphoma (ATLL).
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 23, 2020
Lead Product(s) : Cobomarsen
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cobomarsen
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 12, 2019
Lead Product(s) : Cobomarsen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cobomarsen
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 19, 2018
Lead Product(s) : Cobomarsen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MRG-110
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 27, 2018
Lead Product(s) : MRG-110
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable